{"filing":{"accession_number":"0001213900-26-071799","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"ea0295909-6k_neurosense.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026071799/ea0295909-6k_neurosense.htm"},"events":[{"id":13777,"run_id":12238,"accession_number":"0001213900-26-071799","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive biomarker findings from a Phase 2 proof-of-concept clinical trial (RoAD study) of PrimeC in Alzheimer's disease. The disclosure reports early biological evidence of target engagement across multiple neurodegenerative disease pathways and supports continued development of the drug candidate. While this is a clinical/operational milestone rather than a discrete financial event, earnings release, or governance matter, it represents a material development in the company's drug pipeline that would affect a reasonable investor's assessment of NeuroSense's prospects and strategy in neurodegenerative disease treatment.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":11016,"accession_number":"0001213900-26-071799","item_number":"EX-99.1","item_title":"ea029590901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive biomarker findings from a Phase 2 proof-of-concept clinical trial (RoAD study) of PrimeC in Alzheimer's disease. The disclosure reports early biological evidence of target engagement across multiple neurodegenerative disease pathways and supports continued development of the drug candidate. While this is a clinical/operational milestone rather than a discrete financial event, earnings release, or governance matter, it represents a material development in the company's drug pipeline that would affect a reasonable investor's assessment of NeuroSense's prospects and strategy in neurodegenerative disease treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T13:25:37.767772+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11016,"accession_number":"0001213900-26-071799","item_number":"EX-99.1","item_title":"ea029590901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive biomarker findings from a Phase 2 proof-of-concept clinical trial (RoAD study) of PrimeC in Alzheimer's disease. The disclosure reports early biological evidence of target engagement across multiple neurodegenerative disease pathways and supports continued development of the drug candidate. While this is a clinical/operational milestone rather than a discrete financial event, earnings release, or governance matter, it represents a material development in the company's drug pipeline that would affect a reasonable investor's assessment of NeuroSense's prospects and strategy in neurodegenerative disease treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T13:25:37.767772+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-06-25"}]}